Literature DB >> 18497465

Serum salusin-alpha levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients.

Takuya Watanabe1, Toshiaki Suguro, Kengo Sato, Takatoshi Koyama, Masaharu Nagashima, Syuusuke Kodate, Tsutomu Hirano, Mitsuru Adachi, Masayoshi Shichiri, Akira Miyazaki.   

Abstract

Salusin-alpha is a new bioactive peptide with mild hypotensive and bradycardic effects. Our recent study showed that salusin-alpha suppresses foam cell formation in human monocyte-derived macrophages by down-regulating acyl-CoA:cholesterol acyltransferase-1, contributing to its anti-atherosclerotic effect. To clarify the clinical implications of salusin-alpha in hypertension and its complications, we examined the relationship between serum salusin-alpha levels and carotid atherosclerosis in hypertensive patients. The intima-media thickness (IMT) and plaque score in the carotid artery, blood pressure, serum levels of salusin-alpha, and atherosclerotic parameters were determined in 70 patients with essential hypertension and in 20 normotensive controls. There were no significant differences in age, gender, body mass index, fasting plasma glucose level, or serum levels of high-sensitive C-reactive protein, high- or low-density lipoprotein (LDL) cholesterol, small dense LDL, triglycerides, lipoprotein(a), or insulin between the two groups. Serum salusin-alpha levels were significantly lower in hypertensive patients than in normotensive controls. The plasma urotensin-II level, maximal IMT, plaque score, systolic and diastolic blood pressure, and homeostasis model assessment for insulin resistance (HOMA-IR) were significantly greater in hypertensive patients than in normotensive controls. In all subjects, maximal IMT was significantly correlated with age, systolic blood pressure, LDL cholesterol, urotensin-II, salusin-alpha, and HOMA-IR. Forward stepwise multiple linear regression analysis revealed that salusin-alpha levels had a significantly independent and negative association with maximal IMT. Serum salusin-alpha levels were significantly lower in accordance with the severity of plaque score. Our results suggest that the decrease in serum salusin-alpha, an anti-atherogenic peptide, may be associated with carotid atherosclerosis in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497465     DOI: 10.1291/hypres.31.463

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  15 in total

1.  Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males.

Authors:  Rui Wang; Qiang Lu; Ji Feng; Fuzai Yin; Chunmei Qin; Bo Liu; Yali Liu; Xiaoli Liu
Journal:  Endocrine       Date:  2011-07-28       Impact factor: 3.633

2.  Serum salusin-α levels in systemic lupus erythematosus and systemic sclerosis.

Authors:  Süleyman Serdar Koca; Metin Özgen; Bahar Işık; Mustafa Necati Dağlı; Bilal Üstündağ; Ahmet Işık
Journal:  Eur J Rheumatol       Date:  2014-03-01

3.  IS SALUSIN-ALPHA A NEW MARKER OF CARDIOVASCULAR DISEASE RISK IN HYPOTHYROIDISM?

Authors:  H Usta Atmaca; F Akbas
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jan-Mar       Impact factor: 0.877

4.  Evaluation of salusin-α and salusin-β levels in patients with type 2 diabetes mellitus and determination of the impact of severity of hyperglycemia on salusin levels.

Authors:  Derya Argun; Ferit Argun; Betul Borku Uysal
Journal:  Ir J Med Sci       Date:  2021-06-09       Impact factor: 1.568

5.  Relationship between Serum Salusin Beta Levels and Coronary Artery Ectasia.

Authors:  Arafat Yildirim; Mehmet Kucukosmanoglu
Journal:  Acta Cardiol Sin       Date:  2021-03       Impact factor: 2.672

6.  The role of serum salusin alpha and beta levels and atherosclerotic risk factors in idiopathic sudden hearing loss pathogenesis.

Authors:  Sena Genç Elden; Mahmut Sinan Yılmaz; Mustafa Altındiş; Mehmet Köroğlu; Halil Elden
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-04-18       Impact factor: 2.503

Review 7.  Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease.

Authors:  Takuya Watanabe; Kengo Sato; Fumiko Itoh; Kohei Wakabayashi; Masayoshi Shichiri; Tsutomu Hirano
Journal:  Sensors (Basel)       Date:  2012-04-18       Impact factor: 3.576

8.  Is the serum level of salusin-β associated with hypertension and atherosclerosis in the pediatric population?

Authors:  Urszula Kołakowska; Elżbieta Kuroczycka-Saniutycz; Anna Wasilewska; Witold Olański
Journal:  Pediatr Nephrol       Date:  2014-09-23       Impact factor: 3.714

9.  Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator.

Authors:  Kazumi Fujimoto; Akinori Hayashi; Yuji Kamata; Akifumi Ogawa; Takuya Watanabe; Raishi Ichikawa; Yoshitaka Iso; Shinji Koba; Youichi Kobayashi; Takatoshi Koyama; Masayoshi Shichiri
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

10.  Salusin-β not salusin-α promotes vascular inflammation in ApoE-deficient mice via the I-κBα/NF-κB pathway.

Authors:  Cheng-Hua Zhou; Lian Liu; Lu Liu; Ming-Xing Zhang; Hao Guo; Jin Pan; Xiao-Xing Yin; Teng-Fei Ma; Yu-Qing Wu
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.